Brokerage firm UBS raises target price for MCX shares to 3800 rupees, recommends buying

When choosing the best cryptocurrency to buy now, it might be worth looking at the crypto presale market instead of focusing on established altcoins like SOL, XRP, and ETH. All three of these assets have been in a long-term bear trend for several months.

The Moonberg presale offers traders the opportunity to acquire a utility-focused token supported by an established AI-based crypto trading terminal. Its market capitalization also remains low compared to leading altcoins.

Solana and Ethereum have shown relatively weak price movements over the past few months, and both are struggling to establish a sustained recovery. XRP is lagging even further, and its $1 support level now appears increasingly threatened by sellers. Each of these options presents a different balance between established utility, risk, and potential return. Comparing these factors can help traders determine which of the four coins is the best buy for 2026.

The first phase of the $MBX presale was completed just a few hours after launch, with traders acquiring tokens worth $200,000. $MBX is a utility token within the Moonberg crypto trading terminal, which provides a wide range of features for the established trading community. Moonberg assists with market analysis, blockchain data research, trading strategy development, and AI agent creation without coding.

Moonberg grants access to 53.4 billion data points covering over 76 million tokens. Traders can search for opportunities across multiple blockchains and apply technical indicators. Tools such as Wallet X-Ray and Sentinel also support wallet analysis, whale tracking, and suspicious activity detection. These capabilities are often spread across platforms like Nansen, Dune, and TradingView. Moonberg consolidates them into one terminal, eliminating the need to switch screens. Furthermore, traders can create and deploy personalized AI trading agents without writing code.

Holders of $MBX will gain access to premium analytics, AI computing resources, reduced fees, and priority access. They will also receive access to community-created tools, rewards, and governance rights. The presale offers the earliest opportunity to explore Moonberg before the Token Generation Event (TGE) and potential exchange listings.

Ethereum's price has shown some signs of recovery in the last week. This leading altcoin traded above $4,000 for a long time in 2025, but this year it has lost about 50% of those gains. After falling to $1,600, buyers were able to recover some positions, partly due to increased staked supply. The rise in staking levels reduces the amount of ETH available for sale, which could potentially support the price if demand improves.

In the last week, ETH rose above $1,900, where some analysts expected to find support, but then pulled back to $1,850. Although ETH does not look like an obvious buy right now, it remains a reliable option for long-term holders. It is unlikely to generate massive profits, but historically it has recovered from similar downturns seen this year.

When Solana's price crashed to $71 at the beginning of the month, a repeat of the 2022 crash became a real possibility. Solana has struggled since last year when demand generated by Pump.fun meme coin launches pushed it above $250. Currently, the short-term chart does not look particularly promising, but at $76, SOL is protected from falling below $70.

Despite having a significantly smaller market capitalization compared to Ethereum, volatility is likely to be higher for SOL holders, but the potential return is also greater. Overall, SOL remains a solid long-term buy, although short-term technical analysis indicates risks. Moreover, even optimistic price forecasts from sources like CoinCodex suggest that holders should not expect returns exceeding 20% in the second half of 2026.

XRP's price lags behind $MBX, as well as SOL and ETH. The chart is in a sustained downtrend, with bears recently gaining additional momentum after a bridge exploit that resulted in 200,000 XRP being withdrawn. XRP's price is fighting to hold the $1 support level, although it has occasionally dipped below it for several hours. If a more sustained drop below $1 occurs, stop-loss orders may trigger, causing additional selling pressure from retail traders. At present, XRP is truly only a buy for long-term holders, as short- and medium-term gains remain unlikely.

The Moonberg presale is perhaps the best cryptocurrency to buy right now compared to leading altcoins. While ETH, SOL, and XRP have been fighting for positive momentum, the first phase of the $MBX presale sold out within hours, and more than half of the second phase is now underway. Although a presale is always considered riskier than buying established altcoins, Moonberg has the advantage of an established AI crypto trading terminal with features that can be used and tested before any funds are committed to the presale.

Moonberg is an AI-powered crypto trading terminal that integrates market research, blockchain analysis, strategy development, and trade execution on a single platform. It also allows traders to create and deploy personalized AI agents without writing code.

Ethereum remains a reliable option for long-term holders due to its established ecosystem and historical ability to recover from severe downturns. However, its large market capitalization and weak short-term dynamics may limit potential returns.

Khartis Therapeutics has raised $50 million in a Series B funding round to advance its portfolio of oral medications. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments. Existing investors, including Foresite Capital, Lilly Asia Ventures, and Nextech Invest, also took part in the deal.

With this new capital, Khartis's total raised funds have reached $95 million. This San Diego-based biotechnology company, founded in 2024, specializes in developing oral small molecules for the treatment of chronic and immunological diseases.

Khartis intends to use the received funds to accelerate the development of its lead drug toward clinical trials. Furthermore, the company will continue working on creating drugs targeting validated immunological pathways. The company's core strategy is to create differentiated treatments that can provide increased patient comfort.

The company's main product is a selective inhibitor of the insulin-like growth factor 1 receptor. It is positioned as the first oral selective IGF-1R inhibitor developed for treating thyroid eye disease (TED). TED is an autoimmune condition that can cause inflammation and swelling around the eyes, significantly affecting vision, appearance, and patients' quality of life. Existing treatments can involve serious health risks, so Khartis believes that a selective oral approach can offer a more convenient alternative.

The company aims to achieve a sustainable therapeutic effect alongside an improved safety profile. The team also sees an opportunity to expand access to treatment for underserved patient groups. Craig Murphy, Khartis's Chief Scientific Officer, noted that TED remains a serious burden, and existing treatments often require significant compromises in terms of safety. He added that selective oral inhibition of IGF-1R could change this treatment paradigm, and the program would also serve as a foundation for a broader portfolio.

Khartis was founded by Robert Hoffman, Craig Murphy, and Chris Lemaster. Robert Hoffman serves as CEO and leads drug discovery, while Craig Murphy acts as CSO. Chris Lemaster is the company's Executive Chairman. Previously, the founders worked together at XinThera, which was acquired by Gilead Sciences in 2023. This experience provided Khartis with a strong foundation in drug discovery, which the team is now applying to clinically validated immunological targets.

A representative from Forge Life Science Partners stated that the team demonstrated strong drug discovery capabilities, and the investor believes that Khartis's selective approach can improve the treatment of thyroid eye disease. The firm also expects the company to expand its portfolio beyond the lead product.

Khartis plans to use the new capital to accelerate the development of its lead drug, as well as to further advance additional candidates in the form of oral small molecules targeting immunologically validated pathways. This strategy can reduce the biological uncertainty associated with novel targets. Foresite Capital increased its commitment following the company's early successes. Michael Rom, Managing Director, emphasized the team's consistent work since the Series A round and anticipates the company's progress toward clinical development. The funding provides Khartis with resources to move closer to human testing and offers an extended period to develop a broader therapeutic portfolio, positioning oral drugs as a potentially safer and more convenient treatment option.

Alarming information regarding national security-related arms production has emerged. The Parliamentary Standing Committee issued sharp criticism of the state of small ordnance factories in India. The situation has deteriorated to the point where these factories have incurred significant losses exceeding 600 crore rupees over the past years, and a large portion of production capacity remains idle.

This report concerns Advanced Weapons and Equipment India Limited (AWEIL), a Public Sector Undertaking (DPSU) under the Ministry of Defence, which manufactures small arms in the country. Several important details are revealed in the report.

According to the parliamentary committee's report, between 2015 and 2019, these ordnance factories received extremely low demand from the army. Over five years, the Indian Army accounted for only 10% of the total supply volume. The factories were primarily dependent on orders from the Ministry of Home Affairs (MHA), which proved insufficient to fully utilize the production capacity of all factories.

The committee proposed that the Ministry of Defence, in collaboration with the Ministry of Home Affairs and state police forces, develop a long-term demand plan. This is necessary to prevent factory shutdowns in case of a sudden drop in orders.

The financial condition of the enterprises proved very disheartening. According to the report, between 2015 and 2020, three selected factories incurred a cumulative loss of 366 crore rupees from the production of just 12 types of small arms. Furthermore, in the fiscal year 2023 to 2025, a loss of 234 crore rupees was recorded after the company's establishment.

The problem lies in the fact that the cost of production at the factories is too high, while the market selling price is set below this cost. The committee advised seeking new sources of income, such as by manufacturing hunting and sports rifles and non-lethal equipment for the civilian market, and competing with private defence companies to reduce costs.

The parliamentary committee also expressed serious dissatisfaction with the quality of the manufactured weapons. Inspections revealed numerous serious defects during final inspection. Issues found included material chipping in the chamber (chip-off), low firing rate, and technical flaws in the bolt assembly.

The committee ruled that instead of conducting inspections only at the end, quality control must be carried out throughout the entire production process to ensure that soldiers receive completely safe and high-quality weapons.

The report also noted that inventory management at the factories is extremely inefficient. As of March 31, 2020, these three factories held stock worth 641 crore rupees, representing 72% of the total production value. Meanwhile, 56% of the goods were in process, with this figure rising to 102%.

The committee demanded improvements in inventory management, more accurate demand forecasting, and timely verification of stock levels to avoid unnecessary capital blockage.